Chimeric Therapeutics Halts Trading Pending CDH17 Clinical Trial Results
Key points
- Trading in CHM securities halted pending CDH17 Clinical Trial results
- Halt request made by Chimeric Therapeutics
- Trading halt expected until market opens on August 19, 2026
- No other information necessary to inform the market
Full summary
Chimeric Therapeutics Limited (ASX: CHM) has requested a trading halt on its securities to be effective immediately. The halt is pending the release of material information related to the results of the Company's CDH17 Clinical Trial. The trading halt will remain in effect until the earlier of the commencement of normal trading on Wednesday, August 19, 2026, or the release of the announcement to the market. The Company is not aware of any reason why this trading halt request should not be granted or of any other information necessary to inform the market about the trading halt.
Summary generated by a large language model. Please interpret with care.